A carregar...
ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy
BACKGROUND: Several cancer types harbor alterations in the gene encoding AT-Rich Interactive Domain-containing protein 1A (ARID1A), but there are no approved therapies to address these alterations. Recent studies have shown that ARID1A deficiency compromises mismatch repair proteins. Herein, we anal...
Na minha lista:
| Publicado no: | J Immunother Cancer |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Publishing Group
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7057434/ https://ncbi.nlm.nih.gov/pubmed/32111729 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2019-000438 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|